drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR-T)
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on plasma cells, activating T-cell cytotoxicity to eliminate malignant plasma cells in multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds BCMA (TNFRSF17) on malignant plasma cells; CAR engagement activates T-cell signaling and cytotoxic effector functions (perforin/granzyme release, cytokines) to eliminate multiple myeloma cells.
drug_name
BCMA-directed CAR-T cells
nct_id_drug_ref
NCT06429150